S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:BDTX

Black Diamond Therapeutics Competitors

$23.73
-1.91 (-7.45 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$23.27
Now: $23.73
$26.13
50-Day Range
$23.71
MA: $27.08
$29.76
52-Week Range
$17.63
Now: $23.73
$46.25
Volume371,250 shs
Average Volume486,956 shs
Market Capitalization$857.03 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Black Diamond Therapeutics (NASDAQ:BDTX) Vs. SWTX, RVMD, NK, EDIT, NSTG, and SRNE

Should you be buying BDTX stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Black Diamond Therapeutics, including SpringWorks Therapeutics (SWTX), Revolution Medicines (RVMD), NantKwest (NK), Editas Medicine (EDIT), NanoString Technologies (NSTG), and Sorrento Therapeutics (SRNE).

SpringWorks Therapeutics (NASDAQ:SWTX) and Black Diamond Therapeutics (NASDAQ:BDTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for SpringWorks Therapeutics and Black Diamond Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SpringWorks Therapeutics00303.00
Black Diamond Therapeutics00403.00

SpringWorks Therapeutics presently has a consensus target price of $91.00, indicating a potential upside of 31.31%. Black Diamond Therapeutics has a consensus target price of $51.50, indicating a potential upside of 117.02%. Given Black Diamond Therapeutics' higher probable upside, analysts clearly believe Black Diamond Therapeutics is more favorable than SpringWorks Therapeutics.

Earnings & Valuation

This table compares SpringWorks Therapeutics and Black Diamond Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SpringWorks TherapeuticsN/AN/A$-58,310,000.00($3.55)-19.52
Black Diamond TherapeuticsN/AN/A$-35,260,000.00($16.99)-1.40

SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

76.3% of SpringWorks Therapeutics shares are held by institutional investors. Comparatively, 65.8% of Black Diamond Therapeutics shares are held by institutional investors. 51.2% of SpringWorks Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares SpringWorks Therapeutics and Black Diamond Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SpringWorks TherapeuticsN/A-24.48%-23.58%
Black Diamond TherapeuticsN/A-22.28%-17.91%

Summary

Black Diamond Therapeutics beats SpringWorks Therapeutics on 6 of the 9 factors compared between the two stocks.

Black Diamond Therapeutics (NASDAQ:BDTX) and Revolution Medicines (NASDAQ:RVMD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of current ratings for Black Diamond Therapeutics and Revolution Medicines, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Black Diamond Therapeutics00403.00
Revolution Medicines01402.80

Black Diamond Therapeutics currently has a consensus target price of $51.50, suggesting a potential upside of 117.02%. Revolution Medicines has a consensus target price of $50.75, suggesting a potential upside of 19.55%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Black Diamond Therapeutics is more favorable than Revolution Medicines.

Earnings and Valuation

This table compares Black Diamond Therapeutics and Revolution Medicines' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Black Diamond TherapeuticsN/AN/A$-35,260,000.00($16.99)-1.40
Revolution Medicines$50.04 million56.31$-47,660,000.00N/AN/A

Black Diamond Therapeutics has higher earnings, but lower revenue than Revolution Medicines.

Insider and Institutional Ownership

65.8% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 85.8% of Revolution Medicines shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Black Diamond Therapeutics and Revolution Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Black Diamond TherapeuticsN/A-22.28%-17.91%
Revolution Medicines-191.17%-32.25%-20.55%

Summary

Black Diamond Therapeutics beats Revolution Medicines on 6 of the 8 factors compared between the two stocks.

Black Diamond Therapeutics (NASDAQ:BDTX) and NantKwest (NASDAQ:NK) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of current ratings for Black Diamond Therapeutics and NantKwest, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Black Diamond Therapeutics00403.00
NantKwest00103.00

Black Diamond Therapeutics currently has a consensus target price of $51.50, suggesting a potential upside of 117.02%. NantKwest has a consensus target price of $18.00, suggesting a potential downside of 30.10%. Given Black Diamond Therapeutics' higher possible upside, research analysts plainly believe Black Diamond Therapeutics is more favorable than NantKwest.

Earnings and Valuation

This table compares Black Diamond Therapeutics and NantKwest's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Black Diamond TherapeuticsN/AN/A$-35,260,000.00($16.99)-1.40
NantKwest$40,000.0070,166.82$-65,790,000.00($0.70)-36.79

Black Diamond Therapeutics has higher earnings, but lower revenue than NantKwest. NantKwest is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

65.8% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 9.4% of NantKwest shares are owned by institutional investors. 71.7% of NantKwest shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Black Diamond Therapeutics and NantKwest's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Black Diamond TherapeuticsN/A-22.28%-17.91%
NantKwest-76,658.58%-56.06%-46.93%

Summary

Black Diamond Therapeutics beats NantKwest on 8 of the 11 factors compared between the two stocks.

Black Diamond Therapeutics (NASDAQ:BDTX) and Editas Medicine (NASDAQ:EDIT) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of current ratings for Black Diamond Therapeutics and Editas Medicine, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Black Diamond Therapeutics00403.00
Editas Medicine34302.00

Black Diamond Therapeutics currently has a consensus target price of $51.50, suggesting a potential upside of 117.02%. Editas Medicine has a consensus target price of $49.2222, suggesting a potential upside of 21.96%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Black Diamond Therapeutics is more favorable than Editas Medicine.

Earnings and Valuation

This table compares Black Diamond Therapeutics and Editas Medicine's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Black Diamond TherapeuticsN/AN/A$-35,260,000.00($16.99)-1.40
Editas Medicine$20.53 million132.43$-133,750,000.00($2.68)-15.06

Black Diamond Therapeutics has higher earnings, but lower revenue than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

65.8% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 87.5% of Editas Medicine shares are owned by institutional investors. 0.9% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Black Diamond Therapeutics and Editas Medicine's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Black Diamond TherapeuticsN/A-22.28%-17.91%
Editas Medicine-99.62%-26.74%-16.38%

Summary

Black Diamond Therapeutics beats Editas Medicine on 7 of the 12 factors compared between the two stocks.

Black Diamond Therapeutics (NASDAQ:BDTX) and NanoString Technologies (NASDAQ:NSTG) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of current ratings for Black Diamond Therapeutics and NanoString Technologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Black Diamond Therapeutics00403.00
NanoString Technologies01502.83

Black Diamond Therapeutics currently has a consensus target price of $51.50, suggesting a potential upside of 117.02%. NanoString Technologies has a consensus target price of $63.00, suggesting a potential upside of 3.26%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Black Diamond Therapeutics is more favorable than NanoString Technologies.

Earnings and Valuation

This table compares Black Diamond Therapeutics and NanoString Technologies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Black Diamond TherapeuticsN/AN/A$-35,260,000.00($16.99)-1.40
NanoString Technologies$125.57 million21.41$-40,700,000.00($1.93)-31.61

Black Diamond Therapeutics has higher earnings, but lower revenue than NanoString Technologies. NanoString Technologies is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

65.8% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of NanoString Technologies shares are owned by institutional investors. 4.2% of NanoString Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Black Diamond Therapeutics and NanoString Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Black Diamond TherapeuticsN/A-22.28%-17.91%
NanoString Technologies-53.47%-68.96%-24.15%

Summary

Black Diamond Therapeutics beats NanoString Technologies on 7 of the 12 factors compared between the two stocks.

Black Diamond Therapeutics (NASDAQ:BDTX) and Sorrento Therapeutics (NASDAQ:SRNE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of current ratings for Black Diamond Therapeutics and Sorrento Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Black Diamond Therapeutics00403.00
Sorrento Therapeutics00403.00

Black Diamond Therapeutics currently has a consensus target price of $51.50, suggesting a potential upside of 117.02%. Sorrento Therapeutics has a consensus target price of $28.75, suggesting a potential upside of 226.33%. Given Sorrento Therapeutics' higher possible upside, analysts plainly believe Sorrento Therapeutics is more favorable than Black Diamond Therapeutics.

Earnings and Valuation

This table compares Black Diamond Therapeutics and Sorrento Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Black Diamond TherapeuticsN/AN/A$-35,260,000.00($16.99)-1.40
Sorrento Therapeutics$31.43 million78.73$-292,070,000.00($2.12)-4.16

Black Diamond Therapeutics has higher earnings, but lower revenue than Sorrento Therapeutics. Sorrento Therapeutics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

65.8% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 27.4% of Sorrento Therapeutics shares are owned by institutional investors. 3.4% of Sorrento Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Black Diamond Therapeutics and Sorrento Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Black Diamond TherapeuticsN/A-22.28%-17.91%
Sorrento Therapeutics-698.01%-314.06%-43.60%

Summary

Black Diamond Therapeutics beats Sorrento Therapeutics on 6 of the 10 factors compared between the two stocks.


Black Diamond Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$69.30-7.8%$3.39 billionN/A-39.83Analyst Report
Revolution Medicines logo
RVMD
Revolution Medicines
1.6$42.45-1.7%$2.82 billion$50.04 million0.00Earnings Announcement
Analyst Report
NantKwest logo
NK
NantKwest
1.1$25.75-3.2%$2.81 billion$40,000.00-36.27Decrease in Short Interest
Gap Up
Editas Medicine logo
EDIT
Editas Medicine
1.4$40.36-6.9%$2.72 billion$20.53 million-23.20Analyst Report
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$61.01-12.9%$2.69 billion$125.57 million-35.68Earnings Announcement
Analyst Report
Gap Up
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$8.81-3.0%$2.47 billion$31.43 million-6.03Gap Up
AlloVir logo
ALVR
AlloVir
1.4$34.53-7.5%$2.25 billionN/A0.00Insider Selling
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$45.86-1.9%$2.04 billionN/A0.00
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$10.92-8.7%$1.94 billion$48.83 million-14.37
bluebird bio logo
BLUE
bluebird bio
1.8$27.94-5.0%$1.88 billion$44.67 million-2.54Analyst Report
Vericel logo
VCEL
Vericel
1.5$40.41-4.2%$1.86 billion$117.85 million-4,041,000.00Analyst Report
Analyst Revision
Scholar Rock logo
SRRK
Scholar Rock
1.3$50.60-1.7%$1.70 billion$20.49 million-21.00Upcoming Earnings
News Coverage
Gap Up
Ocugen logo
OCGN
Ocugen
1.1$8.97-16.6%$1.69 billionN/A-6.06Analyst Report
Unusual Options Activity
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$39.07-2.5%$1.68 billionN/A0.00
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.23-0.3%$1.61 billion$102.43 million-18.72Analyst Downgrade
Analyst Revision
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$71.65-16.2%$1.59 billionN/A-48.41Earnings Announcement
Analyst Upgrade
Analyst Revision
Translate Bio logo
TBIO
Translate Bio
1.4$21.29-0.8%$1.58 billion$7.80 million-19.90Upcoming Earnings
Analyst Revision
News Coverage
Replimune Group logo
REPL
Replimune Group
1.5$32.30-1.3%$1.50 billionN/A-18.25News Coverage
REGENXBIO logo
RGNX
REGENXBIO
1.8$39.21-2.4%$1.47 billion$35.23 million-15.81Earnings Announcement
Analyst Downgrade
Analyst Revision
FMTX
Forma Therapeutics
1.8$33.42-8.4%$1.38 billion$100.56 million0.00Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$15.89-0.4%$1.33 billionN/A-3.44Earnings Announcement
Analyst Upgrade
Analyst Revision
Alector logo
ALEC
Alector
1.3$16.25-1.0%$1.29 billion$21.22 million-7.29Analyst Upgrade
Immunovant logo
IMVT
Immunovant
1.8$13.08-7.0%$1.28 billionN/A-10.14Increase in Short Interest
PCVX
Vaxcyte
1.8$23.62-9.4%$1.20 billionN/A0.00Insider Selling
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.25-1.2%$1.11 billion$356.07 million7.47Analyst Report
Mesoblast logo
MESO
Mesoblast
1.4$9.18-0.3%$1.08 billion$32.16 million-10.43Earnings Announcement
Analyst Upgrade
Analyst Revision
Cortexyme logo
CRTX
Cortexyme
1.3$36.37-3.2%$1.07 billionN/A-15.15Earnings Announcement
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$10.96-3.1%$1.07 billion$250,000.00-8.63Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Inhibrx logo
INBX
Inhibrx
1.7$26.56-9.9%$1.00 billionN/A0.00
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$19.25-1.6%$903.15 million$69.89 million-4.59
Passage Bio logo
PASG
Passage Bio
1.9$19.43-2.7%$892.17 millionN/A0.00Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.40-7.7%$883.61 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$10.40-10.4%$844.29 millionN/A-4.86
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.54-12.1%$821.06 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.2$19.31-4.3%$820.41 million$22.99 million-10.27
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.06-6.9%$804.13 millionN/A-9.94
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.29-4.7%$783.28 million$42.74 million-225.44
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.01-4.8%$775.44 million$1.12 million-5.06Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.92-7.4%$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.86-7.3%$667.23 million$2.51 million-4.16Earnings Announcement
Analyst Report
Increase in Short Interest
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.29-6.8%$626.64 millionN/A0.00Decrease in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$30.61-8.2%$622.00 millionN/A0.00Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.16-7.3%$600.87 million$150.05 million-2.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.02-3.1%$578.33 million$22.24 million-5.48Upcoming Earnings
Analyst Report
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.28-17.0%$573.69 millionN/A-1.35
Compugen logo
CGEN
Compugen
1.4$8.16-9.2%$558.31 million$17.80 million-22.05Analyst Downgrade
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.02-7.6%$551.49 million$14.75 million-2.15Gap Up
Curis logo
CRIS
Curis
1.3$9.13-6.4%$537.00 million$10 million-11.13Increase in Short Interest
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.90-2.5%$533.93 million$13.29 million-9.86Upcoming Earnings
News Coverage
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$8.83-12.0%$533.77 millionN/A-4.29Upcoming Earnings
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.